Navigation Links
Growth Opportunity in Brazil's Varicose Vein Treatment Device Market
Date:4/27/2009

Minimally invasive varicose vein treatment market is largely underpenetrated, according to Millennium Research Group

WALTHAM, Mass., April 27 /PRNewswire/ -- According to Millennium Research Group's (MRG's) Opportunities in Brazil: Varicose Vein Treatment Device Market 2009 report, Brazil is extremely underpenetrated with respect to minimally invasive varicose vein treatment devices. The varicose vein treatment device market in the country, widely considered to be one of the most aesthetically-conscious in the world, is limited primarily by the Brazilian universal public health system, which provides reimbursement for surgical vein removal (stripping) procedures but not for more advanced, minimally invasive procedures such as endovenous ablation and sclerotherapy. As a result, patients must pay for these treatments out-of-pocket. Nevertheless, procedure volumes for these minimally invasive alternatives will increase by approximately 10% annually from 2009 to 2013 due to growing patient demand for the superior cosmetic results and reduced postoperative pain associated with these therapies.

Surgical stripping currently remains the gold standard for varicose vein treatment in Brazil because the procedure is extremely cost-effective for the patient and physicians do not need to purchase capital equipment in order to perform the procedures. Surgical stripping is, however, a highly traumatic procedure for the patient, and recovery time is much longer than with newer, minimally invasive treatments. Because the government does not cover the costs for the minimally invasive alternatives, which can cost the patient approximately $1500 per procedure, patients must pay completely out-of-pocket. In contrast, the cost to the patient for a surgical stripping and ligation procedure in the public system, coupled with a 2-night stay in the hospital, is approximately $300, making surgical stripping one of the most affordable treatment options for varicose veins in all of Latin America.

"It is virtually impossible for newer, more expensive treatments to compete within the public health system," says Darren Navarro, Senior Analyst at MRG. "Instead, use of these newer technologies remains confined to the private health system, which serves a more affluent demographic in Brazil. Foreign device manufacturers planning to enter the Brazilian market will need to fully understand Brazil's driving and limiting factors in order to optimize market entry and capitalize on this underpenetrated market."

MRG's Opportunities in Brazil: Varicose Vein Treatment Device Market 2009 report provides coverage of key competitors, including AngioDynamics, biolitec, Codman, Dornier Medtech, Helmeyster, LeMaitre Vascular, MedArt, Vascular Solutions, VNUS Medical Technologies, and more.

About Millennium Research Group

Millennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through syndicated reports, ongoing Marketrack(TM) projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Amy Krohn
    Millennium Research Group
    416-364-7776 x101
    akrohn@mrg.net

    Elizabeth Marshall
    Decision Resources Inc.
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Biometric Market - A Recession Proof Area of Growth and Opportunities, Says Frost & Sullivan
2. Statins may exert influence on prostate cancer growth by reducing inflammation
3. Growth of Plastic Surgery & Botox Grannies in UK
4. STIX Market Research Celebrates Ten Years of Technology/Market Analysis, Custom Research, and Niche Publishing; Prepares New Growth Phase
5. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
6. Researchers find drug that inhibits acute leukemia cell growth
7. Novel cancer drug reduces neuroblastoma growth by 75 percent
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
9. Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009
10. Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth
11. Saebo United Kingdom Posts Record 2008; Sees Continued Growth in UK for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... MA (PRWEB) , ... June 23, 2017 , ... ... Care Reconciliation Act (BCRA), their proposed healthcare bill to repeal and replace the ... May, the Senate bill would make significant cuts to Medicaid, a public health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when ... read it, and some people don't like it at all. FindaTopDoc took a look ... , Erotic literature can give readers a taste of their deepest, darkest fantasies and ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South Asia Leaders Selected ... from government, business and civil society in 11 countries across the Middle East and ... in a transformative exchange of knowledge and ideas with the leading minds in their ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ulster University, Magee Campus in Northern Ireland is ... 3 pm to present to graduate students exciting new and innovative hope research based ... led by The Health Improvement Service of the Western Health & Social Care Trust ...
(Date:6/23/2017)... ... June 23, 2017 , ... Moore Insurance, an eastern Texas ... to asset protection and financial planning services, is teaming up with the For ... of children with cancer and other chronic diseases. , The For A Day ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
Breaking Medicine Technology: